245 related articles for article (PubMed ID: 34206927)
1. Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease.
Leierer J; Perco P; Hofer B; Eder S; Dzien A; Kerschbaum J; Rudnicki M; Mayer G
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206927
[TBL] [Abstract][Full Text] [Related]
2. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
[TBL] [Abstract][Full Text] [Related]
3. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
[TBL] [Abstract][Full Text] [Related]
4. Urinary renin-angiotensin markers in polycystic kidney disease.
Salih M; Bovée DM; Roksnoer LCW; Casteleijn NF; Bakker SJL; Gansevoort RT; Zietse R; Danser AHJ; Hoorn EJ
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F874-F881. PubMed ID: 28747358
[TBL] [Abstract][Full Text] [Related]
5. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
6. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191
[TBL] [Abstract][Full Text] [Related]
7. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
8. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
[TBL] [Abstract][Full Text] [Related]
9. The association of urinary epidermal growth factors with ADPKD disease severity and progression.
Harskamp LR; Perez-Gomez MV; Heida JE; Engels GE; van Goor H; van den Heuvel MC; Streets AJ; Ong ACM; Ortiz A; Gansevoort RT;
Nephrol Dial Transplant; 2023 Sep; 38(10):2266-2275. PubMed ID: 36914219
[TBL] [Abstract][Full Text] [Related]
10. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
11. Urinary angiotensinogen, related factors and clinical implications in normotensive autosomal dominant polycystic kidney disease patients.
Kurultak I; Sengul S; Kocak S; Erdogmus S; Calayoglu R; Mescigil P; Keven K; Erturk S; Erbay B; Duman N
Ren Fail; 2014 Jun; 36(5):717-21. PubMed ID: 24625116
[TBL] [Abstract][Full Text] [Related]
12. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
[TBL] [Abstract][Full Text] [Related]
13. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
14. Urinary biomarkers at early ADPKD disease stage.
Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
[TBL] [Abstract][Full Text] [Related]
15. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
16. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease.
Zheng D; Wolfe M; Cowley BD; Wallace DP; Yamaguchi T; Grantham JJ
J Am Soc Nephrol; 2003 Oct; 14(10):2588-95. PubMed ID: 14514736
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor-β1 in Autosomal Dominant Polycystic Kidney Disease Patients.
Kocer D; Karakukcu C; Ozturk F; Eroglu E; Kocyigit I
Ther Apher Dial; 2016 Oct; 20(5):517-522. PubMed ID: 26991810
[TBL] [Abstract][Full Text] [Related]
19. The association of endothelin-1 levels with renal survival in polycystic kidney disease patients.
Kocyigit I; Eroglu E; Kaynar AS; Kocer D; Kargi S; Zararsiz G; Bayramov R; Imamoglu H; Sipahioglu MH; Tokgoz B; Dundar M; Oymak O
J Nephrol; 2019 Feb; 32(1):83-91. PubMed ID: 30022320
[TBL] [Abstract][Full Text] [Related]
20. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
